Muscle Pharm Corp. develops and manufactures nutritional supplements designed to enhance athletic performance. The company today announced former Assistant Surgeon General Dr. Roscoe M. Moore, Jr. as its new chief scientific director.

Cory Gregory, president of MusclePharm, said Dr. Moore’s position will support the company’s progress toward its current and future objectives and operations.

“We are honored and excited that Dr. Roscoe M. Moore, Jr. is joining our company as chief scientific director. His experience and knowledge in the medical field and his background within the FDA and US Public Health Services will be a tremendous asset to MusclePharm. In addition to overseeing our next generation of product offerings, he will assist in our path toward insurance reimbursement for our Re-Con product for HIV patients suffering from involuntary weight loss and catabolic cachexia, which is a very large market,” Gregory stated in the press release. “Dr. Moore’s decision to join MusclePharm is a reinforcement of the quality and effectiveness of our products and our strong research and developments efforts.”

MusclePharm last month presented information of its Re-Con product to more than 200 attendees at the XVIII International Aids Conference in Vienna, Austria, sponsored by NAPWA and The AIDS Institute. Re-Con has demonstrated clinical attributes to fight the involuntary weight loss and catabolic cachexia associated with HIV patients on highly active antiretroviral therapy (HAART).

Dr. Moore noted the concern and risks of involuntary weight loss in patients with HIV, and said his position with MusclePharm will give him the opportunity to actively address those concerns.

“Unintentional and involuntary weight loss in people living with HIV/AIDS have long been recognized as a serious consequence of this disease. The nutritional requirements among persons undergoing antiretroviral therapy have not been adequately and systematically addressed. Therapeutic nutritional supplementation products, like those provided by MusclePharm, are essential in maintaining the health status of HIV/AIDS patients. I look forward to joining MusclePharm in order to provide the most effective evidence-based approach to assure appropriate and adequate therapeutic nutritional supplementation to mitigate the impact and progression of wasting syndrome in HIV/AIDS patients,” Dr. Moore stated.

For more information visit http://www.musclepharm.com

Let us hear your thoughts below: